Serum Soluble ST2 and Plaque Vulnerability in Patients With Acute Coronary Syndrome
NCT ID: NCT04797819
Last Updated: 2021-03-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
120 participants
OBSERVATIONAL
2019-01-01
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
OCT Evaluation of Early Vascular Repair in Patients With Non ST Elevation Acute Coronary Syndrome (NSTE-ACS)
NCT04375319
Multicenter Registry of Very Early and Late Clinical Outcomes to Everolimus-eluting Cobalt-Chromium Stent In Patients With ST Elevation Myocardial Infarction
NCT02792920
Identification of Predictors for Coronary Plaque Erosion in Patients With Acute Coronary Syndrome
NCT03479723
Coronary Microvascular Dysfunction in Angina Patients With Non-obstructive Coronary Artery Disease (ANOCA-CMD)
NCT06503640
Risk Factors Promoting Coronary Plaque Progression In China
NCT02692014
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Serum sST2 level < 14.5 ng/mL
Coronary plaque components
Coronary plaque components were detected by CCTA method
14.5 ng/mL ≤ Serum sST2 level < 20.5 ng/mL
Coronary plaque components
Coronary plaque components were detected by CCTA method
20.5 ng/mL ≤ Serum sST2 level < 25.9 ng/mL
Coronary plaque components
Coronary plaque components were detected by CCTA method
Serum sST2 level ≥ 25.9 ng/mL
Coronary plaque components
Coronary plaque components were detected by CCTA method
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Coronary plaque components
Coronary plaque components were detected by CCTA method
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Non-ST-elevation myocardial infarction
2. Unstable angina
2. Age from 18 to 75 years
3. Underwent CCTA
Exclusion Criteria
1. Haemodynamic instability
2. Cardiogenic shock
3. Life-threatening arrhythmias or cardiac arrest
4. Mechanical complication
5. Acute heart failure
6. Dynamic ST or T wave changes
7. GRACE score \> 140
2. Patients with previous history of:
1. Coronary artery bypass graft surgery or percutaneous coronary intervention (PCI)
2. Immune system disorder
3. Tumor
4. Acute/chronic infection
5. Statin use within 3 months
6. Atrial fibrillation
7. End-stage renal failure
8. Iodine-containing contrast allergy
3. Patients with no significant (≥ 50%) stenosis on major epicardial vessels after CCTA performance
4. Patients refused subsequent angiography after CCTA performance
5. Patients with total obstruction on major epicardial vessel
6. Patients with insufficient image quality for QAngioCT analysis
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RenJi Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Song Ding
Role: PRINCIPAL_INVESTIGATOR
RenJi Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Cardiology, Ren Ji Hospital
Shanghai, , China
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Luo G, Qian Y, Sheng X, Sun J, Wu Z, Liao F, Feng Q, Yin Y, Ding S, Pu J. Elevated Serum Levels of Soluble ST2 Are Associated With Plaque Vulnerability in Patients With Non-ST-Elevation Acute Coronary Syndrome. Front Cardiovasc Med. 2021 Jul 22;8:688522. doi: 10.3389/fcvm.2021.688522. eCollection 2021.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
sST2 and plaque vulnerability
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.